|
|
Post by JHam on Feb 27, 2017 11:20:42 GMT
|
|
|
|
Post by johank on Feb 27, 2017 13:13:58 GMT
Market likes!!! premarket 300k volume, bid/ask: 1.54/1.55  |
|
|
|
Post by harleyquinn on Feb 27, 2017 13:43:49 GMT
Market likes!!! premarket 300k volume, bid/ask: 1.54/1.55 If I had cash in my account I'd buy more. (I'm still underwater with this one and I think it has further to run. We'll see!) |
|
|
|
Post by happyjawa on Feb 27, 2017 14:40:03 GMT
Man, all the good news and this is still struggling to stay above $1.50. Is the market worried about dilution?
|
|
|
|
Post by jckrdu on Feb 27, 2017 15:10:31 GMT
Man, all the good news and this is still struggling to stay above $1.50. Is the market worried about dilution? That's my belief.
The bullish bet - ONCS releases good news on 2 TAP deals (with some upfront cash/licensing fees) and a drug supply partnership with Merck with some upfront cash, thus extending their cash runway farther into 2018.
The bearish bet - ONCS releases the TAP deals and drug supply partnership news, but without any upfront cash, or a very small amount of upfront cash.
IMO, while both scenarios are possible, I believe the second scenario is more likely. Market seems to think the same, and seems to be expecting more dilution sometime down the road.
I sold my remaining position and will stay on the sidelines until I see the expected "opportunistic" capital raise later this year. Punit alluded to that possibility. Note that capital could be raised at a higher pps if those 3 deals come with a decent chunk of upfront cash... I'm just not seeing that at this point. GL all.
|
|
|
|
Post by happyjawa on Feb 27, 2017 15:25:29 GMT
Man, all the good news and this is still struggling to stay above $1.50. Is the market worried about dilution? That's my belief.
The bullish bet - ONCS releases good news on 2 TAP deals (with some upfront cash/licensing fees) and a drug supply partnership with Merck with some upfront cash, thus extending their cash runway farther into 2018.
The bearish bet - ONCS releases the TAP deals and drug supply partnership news, but without any upfront cash, or a very small amount of upfront cash.
IMO, while both scenarios are possible, I believe the second scenario is more likely. Market seems to think the same, and seems to be expecting more dilution sometime down the road.
I sold my remaining position and will stay on the sidelines until I see the expected "opportunistic" capital raise later this year. Punit alluded to that possibility. Note that capital could be raised at a higher pps if those 3 deals come with a decent chunk of upfront cash... I'm just not seeing that at this point. GL all.
I sold out today for my first ever profit on ONCS. Of course, I sold my long term shares to eliminate the loss from my account (no more huge red spot!) Creates a nice tax shield for me this year, and I managed to up my long term share count by a couple hundred. Not super pleased, but not super disappointed. Whatever happens, things look really bright now. Even if they claim to have enough to operate through 2018, Punit will raise cash if he sees an opportunity. I guess if they dilute some more, it presents a great chance to stock up. I'm confident about this company for the first time in 3 years, so I'll be looking to buy in some more. |
|
|
|
Post by actcfan on Feb 27, 2017 15:28:03 GMT
Great news on the science front. Congrats to holders who are catching a nice spike.
Tend to agree with others, worried about dilution. I sold before the abstract last week thinking it would be sell the news. I still like the story, just worried there will continue to be drifts down and dilution will happen.
Haven't refreshed myself on the cash runway recently, anyone know what it is roughly?
|
|
|
|
Post by jckrdu on Feb 27, 2017 15:33:42 GMT
Great news on the science front. Congrats to holders who are catching a nice spike. Tend to agree with others, worried about dilution. I sold before the abstract last week thinking it would be sell the news. I still like the story, just worried there will continue to be drifts down and dilution will happen. Haven't refreshed myself on the cash runway recently, anyone know what it is roughly? IMO, last word I heard was cash runway was into 1st QTR 2018.
Agree with others that ONCS is looking good longer term.
Can't discount how market will respond if ONCS announces a drug supply partnership with Merck and even $2M-5M upfront cash... that validation could take it much higher. On the other hand ...
I'm worried that those near-term TAP deals are going to be back-ended with some potential cash farther down the road after commercialization, and the market will take it as a sign dilution is coming.
|
|
|
|
Post by happyjawa on Feb 27, 2017 15:35:26 GMT
Great news on the science front. Congrats to holders who are catching a nice spike. Tend to agree with others, worried about dilution. I sold before the abstract last week thinking it would be sell the news. I still like the story, just worried there will continue to be drifts down and dilution will happen. Haven't refreshed myself on the cash runway recently, anyone know what it is roughly? Something like $26 million cash total with a $5-6 million burn per quarter.
|
|
|
|
Post by actcfan on Feb 27, 2017 15:38:48 GMT
Thanks, asked the question then figured I should just look it up. This is from the Dec 8th presentation on the website, so thinking conservative cash position might be around $18-20M. Burning ~$5M/quarter don't think you'd want to let this get below $10-12M, which would mean they need a deal or need to raise by the summer. Just my thoughts.
Strong financial position with $24.4 MM of cash, (as of 10/31/16), no debt; funded through Q1 2018 and multiple key milestones
|
|
